Genome editing company Precision proposes $100M IPO

Genome editing company Precision proposes $100M IPO

Source: 
BioCentury
snippet: 

With plans to bring an allogeneic CAR T immunotherapy into the clinic, Precision BioSciences Inc. (Durham, N.C.) proposed Friday to raise up to $100 million in an IPO on NASDAQ.